Signal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicine

Experimental Oncology

Volumn 26, Issue 3, 2004, Pages 210-216

  Shlapatska, Larysa M ^a   Berdova, Ganna G ^a   Kovalevska, Larysa M ^a   Kulyk, Galyna I ^a   Klein, George ^b   Sidorenko, Svitlana P ^a   Chekhun, Vasyl F ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Burkitt lymphoma; Doxorubicine; MAPK; PKB Akt; Resistance; Signal pathways

Indexed keywords

DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL LINE BL41; CELL LINE DG75; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYMPHOMA CELL; SIGNAL TRANSDUCTION; CHEMICAL ANALYSIS; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STAINING; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BURKITT LYMPHOMA; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOPHENOTYPING; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 7044247327     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Gorman D, Cotter T. Molecular signals in anti-apoptotic survival pathways. Leukemia 2001; 15: 21-34.
2. Arbabi S, Maier RV. Mitogen-activated protein kinases. Crit Care Med 2002; 30: S74-9.
3. Tibbles L, Woodgett J. The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55: 1230-54.
4. Tournier C, Hes P, Yang D, Xu J, Turner T, Nimnual A, Bar-Sagi D, Jones S, Flavell R, Davis R. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-4.
5. Gupta S, Campbell D, Derijard B, Davis R. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389-93.
6. Cavigelli M, Dolfi F, Claret F, Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 1995; 14: 5957-64.
7. Livingstone C, Patel G, Jones N. ATF-2 contains a phosphorylation- dependent transcriptional activation domain. EMBO J 1995; 14: 1785-97.
8. Mansouri A, Ridgway L, Korapati A, Zhang O, Tian L, Wang Y, Siddik Z, Mills G, Claret F. Sustained activation of JNK/p38 MAPK pathways in response to cis-platin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278: 19245-56.
9. Vivo C, Liu W. c-Jun N-terminal kinase contributes to apoptosis synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 2003; 278: 25461-7.
10. Platanias L. Map kinase signaling pathways and hematological malignancies. Blood 2003; 101: 4667-78.
11. Davis R. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
12. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. BAD enables ceramide to signal apoptosis via ras and raf-1. J Biol Chem 1998; 273: 30419-26.
13. van der Brink MR, Kapeller R, Pratt JC, Chang JH, Bukakoff SJ. The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells. J Biol Chem 1999; 274: 11178-85.
14. Dudek H, Datta S, Franke T, Birnbaum M, Yao R, Cooper G, Segal R, Kaplan D, Greenberg M. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-5.
15. Vivanco I, Sawyers Ch. The phosphatidylinositol-3-kinase-Akt pathways in human cancer. Nature Rev 2002; 2: 489-501.
16. Nicholson K, Anderson N. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95.
17. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of P13K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603.
18. Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB. Regulation of Bad phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635-40.
19. Virdee K, Parone P, Tolkovsky A. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol 2000; 10: 1151-4.
20. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
21. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999; 44: 31648-54.
22. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cis-platin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862-8.
23. Yuan Z, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1. J Biol Chem 2003; 278: 23432-40.
24. Boldt S, Weidle U, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002; 23: 1831-8.
25. Ameyar M, Atfi A, Cai Zh, Satncou R, Shatrov V, Bettaieb A, Chouaib S. Analysis of human breast adenocarcinoma MCF7 resistance to tumor necrosis factor-induced cell death. J Biol Chem 1998; 273: 29002-8.
26. Osborn MT, Chamberns TC. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996; 271: 30950-5.
27. Pan Zh, Bruening W, Giasson, Lee V, Godwin K. g-Sunuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 2002; 277: 35050-60.
28. Sidorenko SP, Vetrova EP, Yurchenko OV, Berdova AG, Shlapatskaya LN, Gluzman DF. Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma 1992; 39: 3-9.
29. Mikhalap SV, Shlapatska LM, Berdova GG et al. CDw150 asociated with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 1999; 162: 5719-27.
30. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift imitations in cell lines from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16: 1803-12.
31. Kosako H, Goton Y, Matsuda S, Ishikaaw W, Nishida E. Xenopus MAP kinase activator is a serine/threonine/tyrosine kinase activated by threonine phosphorylation. EMBO J 1992; 11: 2903-8.
32. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-78.
33. Green DR, Red JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
34. Adams J, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
35. 1 in ceramide pathway of apoptosis. Biochem J 1998; 336: 735-41.
36. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. The EMBO J 1999; 18: 3990-4003.
37. Pepper C, Hoy T, Bentley PD. Bcl-2/Bax ratios in chronic lymphocytic leukemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76: 935-8.
38. Vrana JA, Bieszczad CK, Cleaveland ES, Ma Y, Park JP, Mohandas TK, Craig RW. An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-β-D-arabinofurano-sylcytone. Cancer Res 2002; 62: 892-900.
39. Kim R, Tonabe K, Uchida Y et al. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. Cancer Chemother Pharmacol 2002; 50: 343-52.
40. Bing ZC, Kornblau SM, Tsao T, Wang TT, Schober WD, Millela M et al. Capase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitore or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Neoplasia 2003; 102: 4179-86.
41. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig WD, Henze G, Dorken B, Daniel PT. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000; 14: 1606-13.
42. Friedrich K, Wieder T, Haefen C, Radetzki S, Janicke R, Schulza-Osthoff K, Dorken B, Daniel P. Overexpression of caspase-3 restore sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 2001; 20: 2749-60.
43. Birkenkamp KU, Dokter WHA, Esselik MT, Jonk LJC, Kruijer W, Velenga E. A dual function for p38 MAPK kinase in hematopoietic cells: involvement in apoptosis and cell function. Leukemia 1999; 13: 1037-45.
44. Wolfman JC, Palmby T, Der ChJ, Wolfman A. Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. Mol Cell Biology 2002; 22: 1589-606.
45. Mercola D, Murata Yu. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitized human ovarian cancer cell line. J Biol Chem 1999; 274: 31648-54.
46. Weston C, Davis R. The JNK signal transduction pathway. Curr Opin Gen Dev 2002; 12: 14-21.
47. Goillot E, Raingeaud J, Tepper RI, Davis RJ, Harlow E, Sanchez I. Mitogen-activated protein kinase-mediated Fas apoptosis signalling pathways. Proc Natl Acad Sci USA 1997; 94: 3302-7.
48. Lee JR, Koretzky GA. Extracellular signal-regulated kinase-2, but not c-Jun NH2-terminal kinase, activation correlates with surface IgM-mediated apoptosis in the WEHI 231 B cell line. J Immunol 1998; 161: 1637-44.
49. Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry 2000; 65: 59-67.
50. Osborn MT, Chambers TC. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996; 271: 30950-5.
51. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. JNK/MAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int J Cancer 1999; 80: 417-24.
52. Kim AH, Khursiara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 893-901.
53. Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. Activation of apoptosis signal-regulating kinase1 (ASK1) by the adapter protein Dax. Science 1998; 281: 1860-3.